Tuesday, 17, November, 2020

(02:00pm – 03:00pm) (Pakistan Time)

 

Zoom link:

Join from PC, Mac, Linux, iOS or Android:

Click:  https://zoom.us/j/92699513446

Meeting ID: 926 9951 3446

Meeting Password: 614245

 

Registration is Mandatory

https://forms.gle/ogZEUNFknXHKRKch8

 

 

International Faculty Speaker: – 06:00 pm Pakistan time

Prof Nick Gottardo, MBChB, FRACP, PHD

Consultant Paediatric Oncologist/Neuro-Oncologist Head, Department of Paediatric Oncology and Haematology at Perth Children’s Hospital.
Stan Perron Chair in Oncology and Haematology

Nick Gottardo is a clinician/scientist based in Perth, Western Australia. He is a paediatric oncologist/neuro-oncologist and Head of the Department of Paediatric Oncology and Haematology at Perth Children’s Hospital. He is also the Co-leader of the Brain Tumour Research Programme at the Telethon Kids Institute. In June 2018, he was appointed the Stan Perron Chair in Paediatric Oncology and Haematology at Perth Children’s Hospital. He undertook his neuro-oncology fellowship at St Jude Children’s Research Hospital, where he developed extensive experience in mouse model generation and preclinical testing. The Brain Tumour Research Programme focuses on testing novel therapies using mouse model systems that more closely recapitulate the human disease, in order to test the effectiveness of new treatments for childhood brain tumours, so that the most promising therapies can be taken through to the clinic. Nick Gottardo has established a national and international reputation as an expert in paediatric neuro-oncology and is a member of the International Medulloblastoma Working Group.

He is the Chair of the Australian and New Zealand Children’s Haematology/Oncology Group and Chair of the ANZCHOG’s CNS Tumour Group. He leads several international clinical trials, including the AIM-BRAIN Project, SJ-ELiOT and the Children’s Oncology Group’s front-line clinical trial for WNT subgroup medulloblastoma patients, which investigates therapy reduction for this subgroup of patients who have excellent survival on current therapy. In 2019 he was awarded the Australian Society for Medical Research Peter Doherty Leading Light Award, received the Diffuse Intrinsic Pontine Glioma Collaborative, Collaborator of the Year Award, was highly commended by the Western Australian Health Consumers’ Council Consumer Excellence Award and was runner up Cure Cancer Researcher of the Year. In recognition of his contribution to childhood cancer research and clinical care, he has been nominated for Nedlands Citizen of the Year (2018) and Australian of the Year three years in a row (2017, 2018 and 2019) and was a finalist for Western Australian of the Year in 2018.